While beta-emitting therapies like Lu-177 have made strides in cancer care, alpha-emitters offer a new level of precision and potency.
Alpha decays emit helium nuclei, allowing for a greater chance of double-strand breaks in cancer cells.- A high linear energy transfer (LET) allows for delivery of concentrated energy directly to targeted cancer cells
- Efficient integration into targeted radiopharmaceuticals using established chelation chemistry
Despite their enormous potential, alpha-emitters have remained in short supply—hindering its widespread adoption. We are solving this problem.
